Meet with... National Cancer Institute
- Business & Professional
- Johnson & Johnson Innovation, JLABS, South San Francisco CA
Is your company looking for funding? Or simply interested in learning more about global non-governmental life science funding opportunities? Then join us for a chance to hear from one of the world's largest private funders of scientific research, and apply for a one-on-one meeting opportunity with a representative from Wellcome Trust today.
The Wellcome Trust is the UK's largest provider of non-governmental funding for scientific research, with an endowment of over $27 billion (US) for opportunities worldwide. Two leading representatives for the Trust will be in attendance on Wednesday, June 4th to give an overview presentation on the organization's key areas of interest and best practices when seeking funding. Following the presentation, don't miss this opportunity to introduce yourself to the Trust during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with representatives from Wellcome Trust will provide a forum to further discuss your company with representatives of the Trust.
With investment interests in technologies and therapies that address an unmet medical need, leaders from all areas of the life science industry are encouraged to apply today to meet with representatives from Wellcome Trust!
Wednesday June 4, 2014
10:30am | Registration and Networking
11:00am | Presentation and Q&A
11:30am | Networking Lunch
12:30-5:00pm | One-on-one Meetings*
Thursday June 5, 2014
1:00-5:00pm | One-on-one Meetings*
*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends April 25, 2014. APPLY HERE
Wellcome Trust Participating Representatives:
Keith Spencer, PhD | Business Development Analyst, Wellcome Trust read bio»
Tim Jinks, PhD | Senior Business Analyst, Wellcome Trust read bio»
About Wellcome Trust:
Wellcome Trust is a global charitable foundation supporting scientific research. Since 1936, Wellcome Trust has helped bridge the gap between fundamental research and commercial application by funding applied research and development projects to a stage where they are attractive to follow-on funders such as venture capital firms, industry and public-private partnerships. They support a wide array of projects worldwide that address an unfilled medical need or are an enabling tool in healthcare research and development. In 2011, the Trust spent over $1.2 billion (US) on healthcare research.
Presentation & Lunch Only
$30 | General Public
$40 | General Public Onsite
Includes presentation, Q&A, and lunch. Registration to attend the presentation, Q&A, and lunch will remain open until June 3rd.
It is free to apply, but upon acceptance the following fees will apply:
$25 | Accepted Companies
Includes one-on-one meeting only. Companies must have applied for a one-on-one meeting ahead of time. The application period ends on Friday, April 25. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Wellcome Trust Representatives' Biographies:
Keith Spencer, PhD | Business Development Analyst, Wellcome Trust
Keith joined the Trust in 2011. Previously, he worked for Arrow Therapeutics as a Group Leader for anti-infective drug discovery.During his nine year tenure at Arrow, Keith was project leader for multiple programs resulting in the discovery of two clinical candidates for hepatitis C. Keith holds a DPhil in organic chemistry from Oxford University, where he worked under the supervision of Professor Sir Jack E. Baldwin. He subsequently worked as a postdoc at the University of Pennsylvania in Philadelphia. Keith also holds a MChem in Chemistry from the University of St Andrews.
Tim Jinks, PhD | Senior Business Analyst, Wellcome Trust
Tim has over a decade of industry experience most recently as a consultant providing business development, licensing and commercial research services.Previously he was a Business Development executive at BTG International working on licensing and IP development.His industry experience started as senior scientist with Iclectus Ltd, a spin-out company from the MRC Laboratory of Molecular Biology, Cambridge that developed an antibody engineering platform.He trained as a professional chemist at the University of Georgia before gaining his MA and PHD in Molecular Biology at Princeton University.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, and Thomas McNerney & Partners.
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas.
JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation, Inc. any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and Johnson & Johnson Innovation JLABS has now two established locations in San Francisco, one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility, and in Boston, through a collaboration with Lab Central. For more information please visit jlabs.jnjinnovation.com.